Title : The longitudinal triglyceride phenotype in heterozygotes with LPL pathogenic variants - Perera_2022_J.Clin.Lipidol__ |
Author(s) : Perera SD , Wang J , McIntyre AD , Dron JS , Hegele RA |
Ref : J Clin Lipidol , : , 2022 |
Abstract :
BACKGROUND: Biallelic pathogenic variants in lipoprotein lipase (LPL) cause familial chylomicronemia syndrome with severe hypertriglyceridemia (HTG), defined as plasma triglycerides (TG) > 10 mmol/L (> 885 mg/dL). TG levels in individuals with one copy of a pathogenic LPL gene variant is less familiar; some assume that the phenotype is intermediate between homozygotes and controls. OBJECTIVE: We undertook an evaluation of the longitudinal TG phenotype of individuals heterozygous for pathogenic LPL variants. METHODS: Medically stable outpatients were evaluated based on having: (1) a single copy of a rare pathogenic LPL variant; and (2) serial fasting TG measurements obtained over > 1.5 years of follow-up. RESULTS: Fifteen patients with a single pathogenic LPL variant were followed for a mean of 10.3 years (range 1.5 to 30.3 years). TG levels varied widely both within and between patients. One patient had normal TG levels < 2.0 mmol/L (< 175 mg/dL) continuously, while four patients had at least one normal TG level. Most patients fluctuated between mild-to-moderate and severe HTG: five patients had only mild-to-moderate HTG, with TG levels ranging from 2.0 to 9.9 mmol/L (175 to 885 mg/dL), while 6 patients had at least one instance of severe HTG. Of the 203 total TG measurements from these patients, 14.8%, 67.0% and 18.2% were in the normal, mild-to-moderate and severe HTG ranges, respectively. CONCLUSION: The heterozygous LPL deficient phenotype is highly variable both within and between patients. Heterozygosity confers susceptibility to a wide range of TG phenotypes, with severity likely depending on secondary factors. |
PubMedSearch : Perera_2022_J.Clin.Lipidol__ |
PubMedID: 36476373 |
Perera SD, Wang J, McIntyre AD, Dron JS, Hegele RA (2022)
The longitudinal triglyceride phenotype in heterozygotes with LPL pathogenic variants
J Clin Lipidol
:
Perera SD, Wang J, McIntyre AD, Dron JS, Hegele RA (2022)
J Clin Lipidol
: